BiomimX develops advanced organs-on-chip platforms as in vitro pre-clinical models to improve the drug development process. The company proprietary technology uBeat supports 3D cell co-culture and integrates a controlled and tunable mechanical stimulation, leading to the generation of mature and functional miniaturized organs adequate to test compounds toxicity/functionality in a high-throughput fashion. The company organs’ portfolio comprises, among others, uHeart, a human heart-on-chip (winner of StartCup Lombardia 2016), and uKnee, a model of human osteoarthritic joint.

Services: development of in vitro pre-clinical models.

Reference Market: 3d in vitro cultures, in vitro toxicity, DRUG development.